Search
for
Sort by
Research 31–60 of 1000+
- ASSESSMENT OF SOCIODEMOGRAPHIC CHARACTERISTICS AND COMPARATIVE ANALYSIS OF ADVERSE DRUG REACTIONS AMONG OROPHARYNGEAL CANCER PATIENTS RECEIVING DIFFERENT CHEMOTHERAPEUTIC REGIMENS IN KARACHI, SINDH, PAKISTAN
- Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial
- Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
- Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- Severe cutaneous adverse reactions to drugs
- Gefitinib: an adverse effects profile
- Using a capture–recapture method to assess the frequency of adverse drug reactions in a French university hospital
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- An Underrecognized Adverse Effect of Azithromycin
- Many sexual adverse effects of finasteride are attributable to a nocebo effect
- The Differences Between Hormonal Pills and Injection Contraception Adverse Effect: Pekanbaru Puskesmas Case Study
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
- Chemotoxicity in Carcinoma Breast Patients - Its Incidence and Trends in Severity - An Observational Study
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- 1. Medical Practice; Therapy; Adverse Reactions
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
- Pharmacovigilance in Pediatric Patients with Epilepsy Using Antiepileptic Drugs
- Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
- The efficacy and safety of oral minoxidil greater than 5.1-10 mg daily in hair loss disorders
- Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
- Combined Effect of Microneedling and Platelet-Rich Plasma for the Treatment of Acne Scars: A Meta-Analysis
- Dermatologic Care of the Transplant Patient
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Treatments for alopecia areata: a network meta-analysis
- Cosmetovigilance studies to assess the safety of cosmetic therapy in hair segments and skin non-laser
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program